Teva gains after FDA approves monthly schizophrenia injection

Teva said the FDA approved Weltruza, a once-monthly injection for adults with schizophrenia, and expects to launch it in the United States in the coming weeks. Shares rose 5.8% to $41.52; Medincell may receive up to $112 million in additional milestone payments plus royalties.